2024 World Conference on Lung Cancer (WCLC) - Posters-P4.17F.01 Effective EGFR Testing Rates in Advanced Stage NSCLC Patients Treated in Community Oncology Practices: Impact of a Decision Support Program

P4.17F.01 Effective EGFR Testing Rates in Advanced Stage NSCLC Patients Treated in Community Oncology Practices: Impact of a Decision Support Program

Back to course

Pdf Summary

The study focused on measuring the effectiveness of a Decision Support Program (DSP) in improving the rates of Epidermal Growth Factor Receptor (EGFR) testing in advanced stage non-small cell lung cancer (NSCLC) patients in U.S. community oncology clinics. EGFR mutations, like exon 19 deletions, in NSCLC patients are typically treated with targeted therapies, but many patients fail to receive appropriate biomarker testing before treatment, despite its potential benefits. This study aimed to address this gap by implementing a DSP designed by EMOL Health.<br /><br />The DSP included components such as early patient identification, evaluation of candidacy for biomarker testing, and guideline references for treating mutations. The study compared two patient groups: a control group from pre-DSP implementation and a post-implementation intervention group.<br /><br />Key findings indicated that while overall testing rates did not significantly differ between groups (OR 1.33, p=0.35), effective EGFR testing rates increased by 11.9% post-DSP implementation (OR 1.74, p=0.014). Higher DSP interaction, defined as over 20 interactions, marginally improved testing rates. Factors such as having stage IV disease, white race, and smaller tumor size were associated with higher effective testing rates.<br /><br />In terms of treatment following testing, chemotherapy combined with anti-PD1 monoclonal antibodies was the most common regimen, with a median initiation time for EGFR tyrosine kinase inhibitors after test results being seven days. <br /><br />Based on these outcomes, EMOL Health plans to refine the DSP’s logic and patient identification algorithms, and develop a dashboard for real-time testing rates to facilitate benchmarking. Future recommendations include increased education and feedback initiatives to enhance DSP impact. The study was funded by AstraZeneca.

Asset Subtitle

Ray Page

Meta Tag

Speaker Ray Page

Topic Global Health, Health Services & Health Economics

Keywords

Decision Support Program

EGFR testing

non-small cell lung cancer

NSCLC

biomarker testing

targeted therapies

EMOL Health

oncology clinics

DSP implementation

AstraZeneca